CS225117B2 - The purification of insulin - Google Patents
The purification of insulin Download PDFInfo
- Publication number
- CS225117B2 CS225117B2 CS695548A CS554869A CS225117B2 CS 225117 B2 CS225117 B2 CS 225117B2 CS 695548 A CS695548 A CS 695548A CS 554869 A CS554869 A CS 554869A CS 225117 B2 CS225117 B2 CS 225117B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- insulin
- antibodies
- column
- collecting
- substance
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 244
- 102000004877 Insulin Human genes 0.000 title claims abstract description 120
- 108090001061 Insulin Proteins 0.000 title claims abstract description 120
- 229940125396 insulin Drugs 0.000 title claims abstract description 120
- 238000000746 purification Methods 0.000 title description 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims description 16
- 238000002523 gelfiltration Methods 0.000 claims description 10
- 239000012535 impurity Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004202 carbamide Substances 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 101001011741 Bos taurus Insulin Proteins 0.000 claims description 4
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000002608 insulinlike Effects 0.000 claims description 4
- 108010005991 Pork Regular Insulin Proteins 0.000 claims description 3
- 125000000129 anionic group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 10
- 239000012736 aqueous medium Substances 0.000 abstract description 4
- 210000004907 gland Anatomy 0.000 abstract description 3
- 239000004026 insulin derivative Substances 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000005342 ion exchange Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- -1 acetic acid Chemical class 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 101000993800 Sus scrofa Insulin Proteins 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010021001 Hypoglycaemic conditions Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000012801 analytical assay Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS78849A CS225134B2 (cs) | 1969-08-11 | 1978-02-09 | Způsob SiStSní komerčního nebo surového inzulínu |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB38081/68A GB1285023A (en) | 1968-08-09 | 1968-08-09 | Improvements in or relating to injectable insulin preparations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS225117B2 true CS225117B2 (en) | 1984-02-13 |
Family
ID=10401047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS695548A CS225117B2 (en) | 1968-08-09 | 1969-08-11 | The purification of insulin |
Country Status (24)
| Country | Link |
|---|---|
| JP (1) | JPS543931B1 (de) |
| AT (1) | AT354634B (de) |
| BE (1) | BE737257A (de) |
| BG (1) | BG25638A3 (de) |
| BR (1) | BR6911403D0 (de) |
| CA (1) | CA920946A (de) |
| CH (1) | CH526958A (de) |
| CS (1) | CS225117B2 (de) |
| CU (1) | CU33401A (de) |
| DE (1) | DE1940130C2 (de) |
| ES (1) | ES370345A1 (de) |
| FR (1) | FR2015369A1 (de) |
| GB (1) | GB1285023A (de) |
| HK (2) | HK51077A (de) |
| IE (1) | IE33239B1 (de) |
| IL (1) | IL32665A (de) |
| KE (2) | KE2774A (de) |
| MT (1) | MTP620B (de) |
| MY (1) | MY7800209A (de) |
| NL (1) | NL141377B (de) |
| PH (1) | PH12571A (de) |
| SE (1) | SE7901917L (de) |
| YU (2) | YU204569A (de) |
| ZM (1) | ZM12069A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK140801B (da) * | 1975-01-15 | 1979-11-19 | Nordisk Insulinlab | Fremgangsmåde til fremstilling af et stabilt langtidsvirkende insulinpræparat. |
| DE2505306C2 (de) * | 1975-02-07 | 1984-06-07 | Eli Lilly And Co., Indianapolis, Ind. | Verfahren zur Reinigung eines Alkali- oder Ammoniuminsulins |
| NL7713966A (nl) * | 1976-12-27 | 1978-06-29 | Univ Minnesota | Werkwijze voor het behandelen van insuline. |
| DK374579A (da) * | 1979-09-07 | 1981-03-08 | Nordisk Insulinlab | Fremgangsmaade til fremstilling af et injucerbart insulinpraeparat |
| NL193099C (nl) * | 1981-10-30 | 1998-11-03 | Novo Industri As | Gestabiliseerde insuline-oplossing. |
| FI78616C (fi) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| AU1272295A (en) * | 1993-12-17 | 1995-07-03 | Novo Nordisk A/S | Proinsulin-like compounds |
| ZA984697B (en) | 1997-06-13 | 1999-12-01 | Lilly Co Eli | Stable insulin formulations. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1940130U (de) | 1966-02-26 | 1966-06-08 | Heinrich Emil Budesheim | Vorrichtung zum filtern von flussigen oder gasfoermigen medien. |
| DE1966573U (de) | 1967-06-01 | 1967-08-17 | Rainer Sahli | Zylinderschloss an tueren u dgl. raumabschlussorganen. |
-
1968
- 1968-08-09 GB GB38081/68A patent/GB1285023A/en not_active Expired
-
1969
- 1969-07-21 IL IL32665A patent/IL32665A/xx unknown
- 1969-07-21 IE IE1012/69A patent/IE33239B1/xx unknown
- 1969-07-22 CA CA057646A patent/CA920946A/en not_active Expired
- 1969-07-24 ZM ZM120/69A patent/ZM12069A1/xx unknown
- 1969-07-31 CU CU33401A patent/CU33401A/es unknown
- 1969-08-06 CH CH1195769A patent/CH526958A/de not_active IP Right Cessation
- 1969-08-06 BG BG012830A patent/BG25638A3/xx unknown
- 1969-08-06 YU YU02045/69A patent/YU204569A/xx unknown
- 1969-08-07 DE DE1940130A patent/DE1940130C2/de not_active Expired
- 1969-08-07 PH PH10600A patent/PH12571A/en unknown
- 1969-08-07 FR FR6927255A patent/FR2015369A1/fr not_active Withdrawn
- 1969-08-08 BE BE737257D patent/BE737257A/xx not_active IP Right Cessation
- 1969-08-08 BR BR211403/69A patent/BR6911403D0/pt unknown
- 1969-08-08 AT AT768769A patent/AT354634B/de not_active IP Right Cessation
- 1969-08-08 JP JP6283469A patent/JPS543931B1/ja active Pending
- 1969-08-08 ES ES370345A patent/ES370345A1/es not_active Expired
- 1969-08-08 MT MT620A patent/MTP620B/xx unknown
- 1969-08-08 NL NL696912142A patent/NL141377B/xx not_active IP Right Cessation
- 1969-08-11 CS CS695548A patent/CS225117B2/cs unknown
-
1977
- 1977-06-30 YU YU1622/77A patent/YU40003B/xx unknown
- 1977-09-13 KE KE2774A patent/KE2774A/xx unknown
- 1977-09-29 HK HK510/77A patent/HK51077A/xx unknown
- 1977-11-28 KE KE2801A patent/KE2801A/xx unknown
- 1977-12-15 HK HK619/77A patent/HK61977A/xx unknown
-
1978
- 1978-12-31 MY MY1978209A patent/MY7800209A/xx unknown
-
1979
- 1979-03-02 SE SE7901917A patent/SE7901917L/ unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZM12069A1 (en) | 1970-02-16 |
| CU20627L (es) | 1971-08-06 |
| YU204569A (en) | 1982-05-31 |
| CA920946A (en) | 1973-02-13 |
| NL6912142A (de) | 1970-02-11 |
| IE33239B1 (en) | 1974-05-01 |
| MY7800209A (en) | 1978-12-31 |
| SE7901917L (sv) | 1979-03-02 |
| AT354634B (de) | 1979-01-25 |
| ES370345A1 (es) | 1972-01-01 |
| CH526958A (de) | 1972-08-31 |
| KE2774A (en) | 1977-10-21 |
| MTP620B (en) | 1970-01-31 |
| BR6911403D0 (pt) | 1973-03-13 |
| IL32665A0 (en) | 1969-09-25 |
| YU40003B (en) | 1985-06-30 |
| DE1940130C2 (de) | 1983-12-08 |
| CU33401A (es) | 1971-08-06 |
| BE737257A (de) | 1970-02-09 |
| KE2801A (en) | 1978-01-06 |
| BG25638A3 (bg) | 1978-11-10 |
| FR2015369A1 (de) | 1970-04-24 |
| DE1940130A1 (de) | 1970-02-12 |
| HK61977A (en) | 1977-12-23 |
| IE33239L (en) | 1970-02-09 |
| JPS543931B1 (de) | 1979-02-28 |
| PH12571A (en) | 1979-06-20 |
| GB1285023A (en) | 1972-08-09 |
| IL32665A (en) | 1973-05-31 |
| NL141377B (nl) | 1974-03-15 |
| YU162277A (en) | 1982-05-31 |
| HK51077A (en) | 1977-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3950517A (en) | Insulin derivatives | |
| EP0471701B1 (de) | Neue proteine mit tnf-hemmender wirkung und ihre herstellung | |
| US4183849A (en) | Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect | |
| US4343898A (en) | Process for preparing esters of human insulin | |
| DE69127657T2 (de) | Proteinreinigungsmethode | |
| US3869437A (en) | Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin | |
| JPS61212598A (ja) | インシユリン化合物 | |
| MXPA05001042A (es) | Un metodo para purificar preproinsulina. | |
| US3907676A (en) | Process for purifying insulin | |
| FI77876B (fi) | Foerfarande foer framstaellning av humaninsulin eller en treoninb30-ester av humaninsulin eller ett salt eller komplex daerav. | |
| US2174862A (en) | Process of producing crystalline insulin | |
| CS225117B2 (en) | The purification of insulin | |
| US4624804A (en) | Process of preparing relaxin from milk | |
| CA2506594A1 (en) | A method for the crystallization of human serum albumin | |
| Poccia et al. | Developmental changes in chromatin proteins of the sea urchin from blastula to mature larva | |
| GB1576344A (en) | Process for purifying glucagon | |
| Johnson et al. | Feline insular amyloid: immunohistochemical and immunochemical evidence that the amyloid is insulin-related | |
| EP0966482B1 (de) | Kristallisation von proteinen | |
| EP0089218B1 (de) | Verfahren zur Reinigung von menschlichem Choriongonadotropin | |
| US6770455B1 (en) | Metal-containing ribonucleotide polypeptides | |
| US4495096A (en) | Process for producing and obtaining anaphylatoxin-and cocytotaxin-containing leucotaxine preparations and of anaphylatoxin and cocytotaxin proteins in molecularly homogeneous, biologically active form | |
| CA1284000C (en) | Process for recovering glucagon from pancreas glands | |
| FI73130C (fi) | Foerfarande foer framstaellning av renat insulin laempat foer beredning av foer kliniskt bruk anvaendbara injicerbara insulinberedningar. | |
| US2974088A (en) | Method of preparing growth hormone | |
| JPS58212784A (ja) | 卵白リゾチ−ムの結晶化方法 |